There is one clinical trial.
The actual worldwide context (disease outbreak, confinements instaured in many countries) is a stressful factor for many people. It can have consequences on mental health : separation from loved ones, loss of freedom, uncertainty about infection status, boredom. Patients with mental disorders are especially vulnerable. On march 17th, the french government ordonned a national confinement to slow the progression of the COVID-19 outbreak, for 15 days at first then renewed several times. This situation has led to a reorganization of care as requested on March 22nd, 2020 in the recommendations applicable to the organization of care in psychiatric services : priority to telephone contacts and teleconsultation by multiplying contacts and assessments. By the time the reorganization of care became operational, the most vulnerable patients may have experienced a decompensation of their disease. It is important to know if the COVID-19 outbreak combined with the confinement increased the number of unvoluntary commitment the month after the announce of the confinement. This could help us understand which patients are more vulnerable is this context, and improve our organization (ambulatory and hospitalization care) if this situation occurs again.
Description: Number of hospitalized patients From March 12th to April 09thMeasure: Number of hospitalized patients Time: 1 months
Description: Primary psychiatric diagnostic From March 12th to April 09thMeasure: Cause of hospitalization Time: 1 months
Description: Patients without psychiatric antecedent (number) From March 12th to April 09thMeasure: Lengh of hospitalization Time: 1 months
Description: Presence of absence of history of treatment interruption leading to the hospitalization From March 12th to April 09thMeasure: Treatment interruption Time: 1 months
Description: Number of hospitalized patients living alone (opposed to those living with family) From March 12th to April 09thMeasure: Number of hospitalized patients living alone Time: 1 months
Description: Number of patients using drugs From March 12th to April 09thMeasure: Use of drugs Time: 1 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports